KIRKLAND, Wash.--(BUSINESS WIRE)--ProteoTech Inc. (ProteoTech) today announced that Dr. Alan Snow, ProteoTech’s President & Chief Scientific Officer will present an oral presentation at the XIV International Symposium on Amyloidosis.
Dr. Snow’s presentation at the XIV International Symposium on Amyloidosis (Indianapolis, IN) will take place on Thursday May 1, 2014 and is entitled “The Small Molecule SystebrylTM (PTI-110) Causes Potent Disaggregation/Reduction of AL, TTR and AA Amyloidosis”. The International Symposium on Amyloidosis is held every two years and brings together the top amyloid researchers in the world. Dr. Snow will discuss ProteoTech’s lead compound, SystebrylTM (PTI-110) and its ability to disaggregate and reduce amyloid fibril deposits of the AL (immunoglobulin light chain), TTR (transthyretin) and AA (inflammation-associated amyloidosis; AA amyloid) amyloid types.
ProteoTech is a private, therapeutic development Company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolding protein disorders and amyloid diseases. ProteoTech’s lead small molecule compound, Systebryl (PTI-110) will soon be entering Phase 1/2 proof-of-concept studies in AL (immunoglobulin light chain) amyloidosis (an orphan disease). Other drugs in the pipeline, include a small molecule drug inhibitor for TTR (transthyretin) amyloidosis, a small molecule drug inhibitor of alpha-synuclein accumulation (for Parkinson’s disease and other synucleinopathies), and a small molecule drug that works both on the beta-amyloid protein and tau protein of Alzheimer’s disease. For further information, please contact Dr. Roger Flugel, Chief Business Officer (flugel@proteotech.com) or Dr. Alan Snow, President & Chief Scientific Officer (snow@proteotech.com).
For more information: http://www.proteotech.com
